Retatrutide storage: does it need a fridge, and how long does it last once mixed?

Does retatrutide need to be refrigerated?

Nobody has published an official answer, because retatrutide has no approved label anywhere. Eli Lilly still calls it investigational. The defensible default is the one on Lilly's approved tirzepatide label: 2-8C (36-46F) in a refrigerator, protected from light, and never frozen.

Most storage questions have a boring answer: read the label. Retatrutide is the exception, because there is no label to read. In its July 23, 2026 announcement of two more phase 3 results, Eli Lilly described retatrutide as an investigational triple hormone receptor agonist (a drug that activates the receptors for three gut hormones: GIP, GLP-1 and glucagon), said it plans to submit it to the FDA in Q1 2027, and added that it is a molecule that cannot be legally sold or marketed for human use [1].

A storage section is part of an approved label. It is written from stability studies the manufacturer runs on one specific formulation and submits for review. Until that happens for retatrutide, every storage figure you read online, including the ones below, is borrowed from somewhere else. That is worth knowing before you trust any of them.

The closest borrowed answer comes from Lilly itself. Its approved tirzepatide product, Zepbound, is stored in a refrigerator at 2°C to 8°C (36°F to 46°F), kept in the original carton to protect it from light, and never frozen: the label says not to use it if it has been frozen [2]. The label also allows limited time at room temperature, covered below. Those rules were earned by a different molecule in a different formulation, so they are a sensible standard of care, not a guarantee. For the full picture of what retatrutide is and where its trials stand, see our retatrutide TRIUMPH-1 results explainer.

Powder and mixed are two different clocks

Unmixed retatrutide powder and a mixed vial are not the same storage problem. Freeze-dried powder is the more stable form, and water starts the chemistry that breaks peptides down. No published data give a shelf life for either form of retatrutide, so the date printed by a seller is the seller's claim.

Retatrutide sold outside trials is usually a lyophilized powder (freeze-dried, with the water removed) in a sealed vial, and the buyer adds liquid to it. That step, called reconstitution, is the point where the storage clock changes. A formulation review of therapeutic peptides lists the reactions that degrade peptides in water, including oxidation, hydrolysis (water breaking the bonds that hold the chain together) and deamidation (a chemical change to certain amino acid side chains), along with physical problems such as aggregation (molecules clumping) and precipitation [3]. The same review calls lyophilization with suitable stabilizers an ideal approach to keeping peptides intact, and notes that most peptide drugs need cold storage and transport, the cold chain, because of that instability [3].

So the dry powder is the more stable form, and adding water is what starts the problem. What no source gives is a number. We could not find a published stability study of research-grade retatrutide powder, or of a reconstituted retatrutide solution, and the guides that quote shelf lives for it cite none. The expiry date on a research vial is set by whoever filled it, under conditions you cannot check.

The diluent's own label is blunter than most guides. The DailyMed label for bacteriostatic water for injection says "Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute" [4]. For retatrutide bought outside a trial, there is no manufacturer direction to follow. Every multi-week storage plan for a mixed vial is therefore a judgment call, and the rest of this article is about making that call with real numbers rather than a vendor's.

How long does retatrutide last once mixed?

No source gives reconstituted retatrutide a shelf life. The 28 days quoted everywhere is the CDC rule for opened, manufacturer-labeled multi-dose vials, which typically contain a preservative. It caps contamination risk, not potency. A vial mixed with preservative-free sterile water gets no multi-week window at all.

The number you will see most often is 28 days. It is real, but it is not about retatrutide. CDC injection-safety guidance says that once a multi-dose vial is opened (for example, punctured by a needle) it should be dated and discarded within 28 days unless the manufacturer states another date for that opened vial [5]. The same guidance describes multi-dose vials as labeled by the manufacturer and typically containing an antimicrobial preservative to help limit the growth of bacteria [5]. It also counts reconstituting a drug as sterile compounding under USP General Chapter 797 [5].

Read that carefully and three limits fall out. The 28 days is a ceiling, used when no manufacturer gives a shorter or longer date. It is about contamination, not about whether the peptide is still chemically intact. And it assumes a preservative. Bacteriostatic water carries one, 0.9% or 1.1% benzyl alcohol, and is supplied as a multiple-dose container for repeated withdrawals [4]. Plain sterile water does not. CDC describes single-dose containers as typically lacking an antimicrobial preservative and says leftover contents should not be stored for later use [5], so a vial mixed with sterile water is best treated as a single-use preparation, not a 28-day one.

Lilly's own multi-dose tirzepatide shows what a tested window looks like. The Zepbound multi-dose vial contains benzyl alcohol, glycerin and phenol as inactive ingredients, and the label says to throw an opened one away after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first, even if medicine is left [2]. That is a formulation built and tested for repeated use. A research vial of retatrutide powder dissolved in bacteriostatic water at home is not that formulation, and nobody has measured how long it stays potent. Our general guide to how long reconstituted peptides last covers the same distinction for every peptide.

What the approved GLP-1 labels allow, and why it does not transfer

Approved GLP-1 labels do allow time out of the fridge: up to 21 days at up to 30C for a Zepbound single-dose vial, 30 days for its opened multi-dose vial, 56 days for an in-use Ozempic pen. Each window was measured for that exact product, so none of them is a retatrutide number.

Online storage guides often take the generous numbers from approved drugs and attach them to retatrutide. It helps to see the numbers side by side, and what each one is attached to.

A Zepbound single-dose pen or vial can, if needed, be kept unrefrigerated at up to 30°C (86°F) for a total of 21 days, then discarded [2]. An unopened Zepbound multi-dose vial kept at room temperature, up to 30°C (86°F), must be thrown away after 30 days, and an opened one follows the 30-day and 4-dose limits above [2]. Novo Nordisk's Ozempic (semaglutide) pen, once in use, can be kept for 56 days either at 15°C to 30°C (59°F to 86°F) or in a refrigerator at 2°C to 8°C (36°F to 46°F), and its label adds a practical detail: do not store it directly next to the cooling element [6].

Each of those windows belongs to a finished product: a fixed concentration, a fixed set of excipients (the inactive ingredients that keep the drug stable), a fixed container, and stability data reviewed by the FDA. Change any of those and the number no longer applies, which is why even two products containing the same tirzepatide carry different windows. A homemade retatrutide solution changes all of them at once. The honest use of these labels is as an upper bound on what a well-formulated GLP-1 class drug can tolerate, not as a promise that an unformulated research peptide will do the same.

Left out of the fridge, frozen or cloudy

There is no retatrutide data on temperature excursions, so nobody can say how long it survives outside the fridge. A vial that froze, turned cloudy, changed color or shows particles should be discarded: those are the same visual rules the approved tirzepatide label sets for its own vials.

The most common version of this question is the morning after: the vial sat on the counter overnight, or the fridge failed. For an approved drug, the label answers it. For retatrutide, nothing does. The 21-day unrefrigerated allowance on a Zepbound single-dose vial [2] is a measured result for that product, not evidence that a mixed research vial tolerates the same.

What the approved labels do give you is a set of visual discard rules that make sense for any clear injectable solution. Zepbound's instructions say not to use the medicine if it has been frozen, has particles, is cloudy, or is discolored, and describe a normal solution as clear and colorless to slightly yellow [2]. Freezing deserves its own warning because it is easy to do by accident in a home fridge: the Ozempic label says not to store the pen in the freezer or right against the cooling element [6].

The rule that matters most runs the other way. A solution that looks fine can still have degraded. Oxidation and hydrolysis are chemical instability pathways for peptides [3], and confirming whether they have happened takes a laboratory, not a look at the vial. A clear vial is not proof of potency; a cloudy one is proof of a problem. If a mixed vial sat warm for an unknown length of time, the honest position is that its contents are unknown.

Research vials and compounded retatrutide: whose date is it?

No US pharmacy can legally assign compounded retatrutide a beyond-use date. FDA says retatrutide fails the conditions for both kinds of compounding, and a 2024 warning letter called one seller's research use only GLP-1 products unapproved new drugs. Any date on such a vial carries no reviewed stability data.

For approved drugs, two parties can set a storage date: the manufacturer, through the label, and a licensed pharmacy that compounds the drug under the sterile compounding standard CDC points to, USP General Chapter 797 [5], and assigns a beyond-use date. Neither exists for retatrutide.

On the compounding side, an FDA warning letter dated September 9, 2025 spells out why. Drug products compounded using retatrutide are not eligible for the section 503A exemptions, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list, and they fail section 503B because it is not on the 503B bulks list or used to make a drug on the shortage list [7]. FDA concluded that there are no FDA-approved applications on file for those compounded retatrutide products [7].

On the research-chemical side, a December 2024 warning letter to one seller named its retatrutide, semaglutide, tirzepatide, cagrilintide and mazdutide products as unapproved new drugs, despite labels reading "research use only" and "intended as a research chemical only", because the seller's own website showed they were intended for human use [8]. A "research use only" sticker is not a stability claim either. It means nobody has promised you anything about what is in the vial or how long it lasts.

If you are trying to understand retatrutide before deciding anything, the useful step is the one that does not involve a vial: learning what the trials found and what they did not. Our retatrutide course covers the mechanism and the evidence, and the peptide reconstitution guide explains the sterile technique and the arithmetic of mixing for any lyophilized peptide, without telling anyone what to inject.

A storage routine built on what is known

Keep sealed powder refrigerated and dark, mix only when needed, label each vial with the date and the diluent, and treat 28 days as the outside limit for a bacteriostatic-water vial. Treat a sterile-water vial as single use. Discard anything frozen, cloudy, discolored or of unknown temperature history.

Put together, the documents support a short routine, and each step traces to something above. Keep sealed powder at 2°C to 8°C (36°F to 46°F), away from light and never frozen, the refrigerated standard the approved tirzepatide label sets for its own product [2], and keep it off the fridge's cooling element, as the Ozempic label advises for its pens [6]. Mix only when you need to, since the dry form is the stable one [3]. Label the vial the day it is mixed with the date, the diluent and the volume added.

Then apply the strictest rule that fits. With bacteriostatic water, 28 days from first puncture is the outside ceiling, borrowed from CDC's rule for preserved multi-dose vials and covering sterility only [5]. With sterile water, which has no preservative, the contents are best treated as a single-use preparation, for the reason given above. And whatever the calendar says, a vial that froze, clouded, changed color or grew particles goes in the bin [2].

If the vial has to travel, the cold chain becomes the hard part. Our guide to flying with peptides covers airport screening, insulated cases and customs for exactly this situation.